| Compound Information | SONAR Target prediction |
| Name: | ETHOPROPAZINE HYDROCHLORIDE |
| Unique Identifier: | SPE01500293 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 323.735 g/mol |
| X log p: | 17.895 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 31.78 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 5 |
| Canonical Smiles: | Cl.CCN(CC)C(C)CN1c2ccccc2Sc2ccccc12 |
| Source: | synthetic |
| Therapeutics: | antiparkinsonian, anticholinergic |
| Generic_name: | Ethopropazine |
| Chemical_iupac_name: | N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449531 |
| Drugbank_id: | APRD00729 |
| Melting_point: | 64.5 oC |
| H2o_solubility: | 0.693 mg/L |
| Logp: | 5.772 |
| Cas_registry_number: | 08/02/1094 |
| Mass_spectrum: | http://webbook.nist.gov/cgi/cbook.cgi?Spec=C522009&Index=0&Type=Mass&Large=on |
| Drug_category: | Antiparkinson Agents; Antidyskinetics |
| Indication: | For use in the treatment of Parkinson-s disease and also used to control severe reactions to certain medicines such as reserpine. |
| Pharmacology: | Ethopropazine, a phenothiazine and antidyskinetic, is used in the treatment of Parkinson-s disease. By improving muscle control and reducing stiffness, this drug permits more normal movements of the body as the disease symptoms are reduced. It is also used to control severe reactions to certain medicines such as reserpine, phenothiazines, chlorprothixene, thiothixene, loxapine, and haloperidol. Unlike other NMDA antagonists, ethopropazine — because of its anticholinergic action — is largely devoid of neurotoxic side effects. Ethopropazine also has a slight antihistaminic and local anesthetic effect. |
| Mechanism_of_action: | Ethopropazine-s antiparkinson action can be attributed to its anticholinergic properties. Ethopropazine partially blocks central (striatal) cholinergic receptors, thereby helping to balance cholinergic and dopaminergic activity in the basal ganglia; salivation may be decreased, and smooth muscle may be relaxed. Drug-induced extrapyramidal symptoms and those due to parkinsonism may be relieved, but tardive dyskinesia is not alleviated and may be aggravated by anticholinergic effects. Ethopropazine-s local anesthetic effect is due to its antagonism of the NMDA glutamate receptor. Glutamate is recognized as an important transmitter in nociceptive pathways, and the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, in particular, has been implicated in the mediation of neuropathic pain. Excessive release of glutamate at NMDA receptors on dorsal horn neurons of the spinal cord results in hyperactivation and hypersensitivity of these receptors (perceived as hyperalgesia), thought to be an integral feature of neuropathic pain. |
| Organisms_affected: | Humans and other mammals |
| Found: 42 active | as graph: single | with analogs | [1] << Back 11 12 13 14 15 16 17 18 19 20 Next >> [42] |
| Species: | 4932 |
| Condition: | DRS2 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.5209±0.0138593 |
| Normalized OD Score: sc h | 0.7695±0.0186776 |
| Z-Score: | -9.9481±0.78324 |
| p-Value: | 2.88118e-21 |
| Z-Factor: | 0.478254 |
| Fitness Defect: | 47.2961 |
| Bioactivity Statement: | Active |
| ps |
| DBLink | Rows returned: 8 | << Back 1 2 |
| 6919063 | diethyl-[(2S)-1-phenothiazin-10-ylpropan-2-yl]azanium |
| 6921598 | diethyl-[(2R)-1-phenothiazin-10-ylpropan-2-yl]azanium |
| internal high similarity DBLink | Rows returned: 3 |
| LOPAC 00147 | 0.9677 |
| RH 01503 | 0.9677 |
| SPE01500510 | 0.9677 |
| active | Cluster 7451 | Additional Members: 8 | Rows returned: 1 |
| SPE01500510 | 0 |
Service provided by the
Mike Tyers Laboratory